JP7834342B2 - 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 - Google Patents
腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置Info
- Publication number
- JP7834342B2 JP7834342B2 JP2022514645A JP2022514645A JP7834342B2 JP 7834342 B2 JP7834342 B2 JP 7834342B2 JP 2022514645 A JP2022514645 A JP 2022514645A JP 2022514645 A JP2022514645 A JP 2022514645A JP 7834342 B2 JP7834342 B2 JP 7834342B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- adenovirus
- inhibitor
- cdk4
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19000396.2 | 2019-09-05 | ||
| EP19000396 | 2019-09-05 | ||
| EP19000406.9 | 2019-09-12 | ||
| EP19000406 | 2019-09-12 | ||
| PCT/EP2020/074980 WO2021044061A1 (en) | 2019-09-05 | 2020-09-07 | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547885A JP2022547885A (ja) | 2022-11-16 |
| JP2022547885A5 JP2022547885A5 (cg-RX-API-DMAC7.html) | 2023-09-15 |
| JP7834342B2 true JP7834342B2 (ja) | 2026-03-24 |
Family
ID=72428285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514645A Active JP7834342B2 (ja) | 2019-09-05 | 2020-09-07 | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220354911A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025229A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7834342B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220079551A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114615996A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020342594A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3152965A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021044061A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4578943A4 (en) * | 2022-08-25 | 2026-02-25 | Fujifilm Corp | PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016516407A (ja) | 2013-03-14 | 2016-06-09 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| WO2016178167A1 (en) | 2015-05-04 | 2016-11-10 | Vcn Biosciences Sl | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
| JP2017501187A (ja) | 2013-12-31 | 2017-01-12 | シュエンジュウ・ファーマ・カンパニー・リミテッド | キナーゼ阻害剤及びその使用 |
| JP2017516862A (ja) | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| JP2021517119A (ja) | 2018-03-05 | 2021-07-15 | クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2003242585A1 (en) | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| WO2012022496A2 (en) * | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| ES2899913T3 (es) * | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| WO2018195202A1 (en) * | 2017-04-21 | 2018-10-25 | Pellficure Pharmaceuticals Inc. | Compositions and methods for the treatment of cancer |
| CA3066778A1 (en) * | 2017-06-21 | 2018-12-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
-
2020
- 2020-09-07 WO PCT/EP2020/074980 patent/WO2021044061A1/en not_active Ceased
- 2020-09-07 EP EP20768332.7A patent/EP4025229A1/en active Pending
- 2020-09-07 KR KR1020227011226A patent/KR20220079551A/ko active Pending
- 2020-09-07 CA CA3152965A patent/CA3152965A1/en active Pending
- 2020-09-07 AU AU2020342594A patent/AU2020342594A1/en active Pending
- 2020-09-07 US US17/640,720 patent/US20220354911A1/en active Pending
- 2020-09-07 CN CN202080070210.1A patent/CN114615996A/zh active Pending
- 2020-09-07 JP JP2022514645A patent/JP7834342B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016516407A (ja) | 2013-03-14 | 2016-06-09 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| JP2017501187A (ja) | 2013-12-31 | 2017-01-12 | シュエンジュウ・ファーマ・カンパニー・リミテッド | キナーゼ阻害剤及びその使用 |
| JP2017516862A (ja) | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| WO2016178167A1 (en) | 2015-05-04 | 2016-11-10 | Vcn Biosciences Sl | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
| JP2021517119A (ja) | 2018-03-05 | 2021-07-15 | クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 |
Non-Patent Citations (8)
| Title |
|---|
| Abstracts des 71. Kongresses der Deutschen Gesellschaft fur Urologie e.V.,2019年08月20日,S101, V36.6 |
| Annual Review of Pharmacology and Toxicology,2009年,Vol.49,pp.223-241 |
| Cancers,2019年05月16日,Vol.11, No.684,pp.1-22 |
| Digestive diseases and sciences,2008年,Vol. 54,No. 7,pp.1425-1431 |
| Eur. Urol. Suppl.,2015年,Vol.14 No.2,p.e32 |
| Molecular Oncology,2014年,Vol. 9, No. 4,p.791-805 |
| Nature Communications,2022年08月10日,Vol. 13,No. 1, #4689,pp.1-18 |
| Oncolytic Viral Therapy brochure,2019年04月19日,https://www.pegsummit.com/Oncolytic-Viral-Therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022547885A (ja) | 2022-11-16 |
| CN114615996A (zh) | 2022-06-10 |
| AU2020342594A1 (en) | 2022-03-10 |
| CA3152965A1 (en) | 2021-03-11 |
| WO2021044061A1 (en) | 2021-03-11 |
| US20220354911A1 (en) | 2022-11-10 |
| KR20220079551A (ko) | 2022-06-13 |
| EP4025229A1 (en) | 2022-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3777843B1 (en) | Drug delivery particle and method for producing the same | |
| JP2025013934A (ja) | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 | |
| Alonso et al. | ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo | |
| Li et al. | Sox9 activation is essential for the recovery of lung function after acute lung injury | |
| Vaughan et al. | p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity | |
| Holzmüller et al. | YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma | |
| Aguirre-Hernández et al. | Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy | |
| Wang et al. | METTL14 promotes vascular smooth muscle cell proliferation and neointima formation via m6A methylation TEAD1 mRNA | |
| Yin et al. | VEGF blockade decelerates the growth of a murine experimental osteosarcoma | |
| He et al. | Adenovirus-mediated over-expression of Septin4 ameliorates hepatic fibrosis in mouse livers infected with Schistosoma japonicum | |
| JP2022547885A (ja) | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 | |
| RU2835886C1 (ru) | Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента | |
| RU2811278C2 (ru) | Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6 | |
| CN102056631B (zh) | 细胞凋亡诱导物 | |
| Wang et al. | HSF1 overexpression enhances oncolytic effect of replicative adenovirus | |
| Srivastava et al. | Mode of cell death associated with adenovirus-mediated suicide gene therapy in HNSCC tumor model | |
| Zang et al. | Chromatin remodeling factor CHRAC1 regulates doxorubicin-induced cardiotoxicity via IRF9/GSDMD/CASP-1 | |
| Li et al. | microRNA response element‑regulated TIKI2 expression suppresses the tumorigencity of malignant gliomas | |
| Klein | Investigation of replication kinetics and cell killing capacity of the oncolytic adenovirus XVir-N-31 in conjunction with targeted therapy | |
| Zhang et al. | S-RBD-modified and miR-486-5p-engineered exosomes derived from mesenchymal stem cells alleviate radiation-induced lung injury and long-term pulmonary fibrosis via suppression of ferroptosis | |
| Mckiver | SND1-Targeted Gene Therapy for Hepatocellular Carcinoma | |
| Wang et al. | Research HSF1 overexpression enhances oncolytic effect of replicative adenovirus | |
| Strauss | ANALYSIS OF RESISTANCE OF PRIMARY OVARIAN CANCER CELLS TO VIRAL ONCOLYSIS DISSER TAT ION zur Erlangung des akademischen Grades doctor rerum naturalium | |
| Aguirre | The oncolytic adenoviral AdΔΔ mutant sensitizes prostate cancer cells to mitoxantrone by promoting apoptosis and attenuating autophagy | |
| Breslin et al. | Alan Wei-Shun Tseng, Chiachen Chen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230906 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230906 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240910 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250310 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250507 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250904 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260304 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7834342 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |